GSK Industry Symposium

GSK Industry Symposium

B-cell maturation antigen (BCMA)-targeted agents:
Emerging clinical considerations for a new pillar of therapy for the treatment of relapsed/refractory multiple myeloma (RRMM)

Friday, May 7, 2021 – 11:45-13:15 CEST

Francesca Gay, MD, PhD
Torino, Italy
University of Torino

Suzanne Trudel, MD, MSc
Toronto, Canada
Princess Margaret Cancer Centre

OBJECTIVES:

  • Explore recent support for the role of BCMA-targeted therapy in the management of multiple myeloma
  • Assess evidence of efficacy for BCMA-targeted therapy in patient subpopulations
  • Review scientific rationale and investigational regimens combining BCMA-targeted therapy with the standard of care

AGENDA:

11:45-11:50 Welcome and Introductions
Francesca Gay, MD, PhD
11:50-12:10 BCMA-targeted therapies: the 4th pillar in treating relapsed/refractory multiple myeloma
Francesca Gay, MD, PhD
12:10-12:25 Assessing patient eligibility for BCMA-targeted therapies in relapsed/refractory multiple myeloma
Suzanne Trudel, MD, MSc
12:25-12:45 The rationale for combination regimens incorporating BCMA-targeted therapies
Suzanne Trudel, MD, MSc
12:45-13:05 Q&A
All
13:05-13:15 Closing remarks
Suzanne Trudel, MD, MSc
Symposium Evaluation Form